Latest news with #BioHealx
Business Wire
3 days ago
- Health
- Business Wire
Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas
STATEN ISLAND, N.Y.--(BUSINESS WIRE)--Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx ®Anal Fistula Device - offering new hope to patients suffering from complex and often debilitating anal fistulas. The procedures were performed by colorectal surgeons Poppy Addison, MD, and Giovanni Bonomo, MD, director of colorectal surgery. The BioHealx device, developed by Irish-based Signum Surgical, represents a significant advancement in the treatment of complex anal fistulas, notoriously difficult to treat with current surgical options. The minimally invasive, absorbable implant is designed to close fistula tract as it traverses the anal sphincter complex, without involving any significant disruption of the anorectal anatomy. Early European data demonstrated an 84% success rate, far exceeding traditional approaches that often have success rates closer to 60% and are associated with the need for multiple procedures to finally achieve healing. 'Historically, these surgeries have been long, complex, traumatic to the anorectum and carried the risk of recurrence and incontinence,' said Dr. Bonomo. 'The BioHealx device is intuitive, efficient, and minimizes surgical trauma. If we can replicate the European outcomes, this could set a new standard of care in fistula treatment.' Approximately, 90,000 complex anal fistula procedures are performed yearly. These fistulas predominantly affect men between ages 18 and 50, and disrupts their quality of life due to anal pain, foul-smelling drainage, and recurrent infection. Fistulas can recur even after what appears to be healing at the skin level due to persistence of the transsphincteric fistula tract, and many patients undergo multiple interventions before finding relief. 'Rectal fistulas are under-researched and have lacked a reliable, standardized solution,' said Dr. Addison. 'This device has the potential to optimize care, shorten recovery, and reduce recurrence, all while preserving continence, which is a critical concern for our patients.' Before surgery, a seton drain is placed to help mature the fistula tract and to provide for clear identification of the internal fistula opening. During the BioHealx procedure, the seton is removed, the tract is brushed clean, and a small flap is created to expose the internal sphincter at the location of internal opening. The corkscrew-shaped BioHealx implant is then inserted to compress the tissue around the fistula tract as it traverses the width of the sphincter complex to deliver primary healing by direct tissue apposition. The flap is closed over the internal opening and internal anal sphincter, while the outer tract is partially opened for optimal drainage - all without damaging the sphincter muscle nor disrupting the anal canal. The implant itself is made from bioabsorbable polylactic glycolic acid and naturally dissolves in the body within six to twelve months, leaving no permanent material behind. The inspiration for the BioHealx device dates back to 2013 when engineers Eoin Bambury and Moshe Zilversmit, co-founders of Signum Surgical, met during a government-sponsored fellowship in Ireland. After observing the repeated failure of traditional surgeries to treat anal fistulas, often requiring four or more operations, they launched Signum Surgical in 2016 to develop a better solution. 'The key was identifying the failure of primary healing of the transsphincteric portion of the fistula tract as the root cause of surgical failure,' said Bambury. 'Our goal was to close it effectively without damaging the anal canal nor the anal sphincter. After years of research, clinical trials, and design refinement, we're proud to see our work helping patients here in the U.S.' SIUH's successful completion of the first U.S. procedures using the BioHealx device represents a critical milestone in the adoption of innovative, patient-centered technology across Northwell Health. 'Northwell has always championed advanced technologies that improve outcomes and quality of life,' said Dr. Bonomo. 'This is the kind of breakthrough that can change how we treat complex anal fistulas nationwide.' Drs. Bonomo and Addison will continue evaluating patient outcomes to help guide future adoption and research of the BioHealx procedure. With a shorter learning curve than many other surgical techniques, the team believes the procedure can be easily adopted across the entire system. 'We're incredibly optimistic,' said Dr. Addison. 'This device doesn't burn any bridges - it's safe, effective, and easy to use. If it doesn't work, patients still have all their future options with essentially normal anorectal anatomy. But if it does, it can spare them years of painful, frustrating treatments.'
Business Wire
12-05-2025
- Health
- Business Wire
Signum Surgical Publishes Positive First-in-Human Results for BioHealx® Anal Fistula Device
GALWAY, Ireland--(BUSINESS WIRE)--Signum Surgical, a medical technology company dedicated to advancing the treatment of colorectal diseases, today announced the publication of first-in-human clinical data for its BioHealx® Anal Fistula Device in the International Journal of Colorectal Disease. The results support recent De Novo clearance by the U.S. Food and Drug Administration (FDA) and mark a significant milestone in the development of this innovative treatment. Positive First-in-Human Results for BioHealx® Anal Fistula Device supports U.S. FDA De Novo clearance and sets the stage for U.S. launch Share The prospective, multi-center first-in-human study was conducted in Budapest and Szeged, Hungary, and followed 32 patients diagnosed with transsphincteric cryptoglandular fistulas over a 12-month period. The study evaluated the BioHealx® device as part of the BioHealx-Assisted Fistula Treatment (BAFT) procedure, assessing both fistula and wound healing outcomes. Key findings include: 84.4% primary healing rate without recurrence of the fistula 96.8% preservation of fecal continence-related quality of life No device-related adverse events or migrations reported The BioHealx® device is a novel bioabsorbable implant made from PLGA 8218, designed to close the internal opening of the fistula while maintaining external drainage during healing. Its helical coil shape enables compression-based tissue apposition, promoting primary healing without compromising sphincter function. 'These results demonstrate the potential for BioHealx to redefine the treatment of transsphincteric fistulas,' said Peter Ónody, Colorectal Surgeon and study investigator. 'The technique was intuitive, and the clinical outcomes are among the most promising we've seen in managing this challenging condition.' 'Our team is proud to introduce the first therapy that offers direct compression closure of the fistula tract within the anal sphincter complex,' said Carol A. Burns, CEO of Signum Surgical. 'We believe BioHealx will be a transformative option for both patients and surgeons. Following FDA clearance, we are preparing for a limited commercial launch in select U.S. centers and will begin enrollment in a 50-patient Post-Market Surveillance study.' Dr. Anthony Senagore, Chief Medical Officer, added: 'Anal fistula disease remains one of the most complex issues in colorectal surgery, with existing treatments often falling short. BioHealx offers a minimally invasive, sphincter-preserving alternative with durable outcomes and high patient quality of life.' About Anal Fistulas Anal fistulas affect primarily men aged 18–50 and can severely impact quality of life, causing pain, incontinence, abscesses, and frequent recurrence. Despite being described as early as Hippocrates, treatment options remain limited and often involve risk to continence. About BioHealx® The BioHealx® Anal Fistula Device is a bioabsorbable, single-use implant delivered under direct visualization. It is designed to close the fistula tract via compression-induced tissue healing, offering a sphincter-preserving approach to treating transsphincteric fistulas. BioHealx has received U.S. FDA De Novo 510(k) clearance.
Associated Press
12-03-2025
- Business
- Associated Press
Signum Surgical Appoints Carol Burns as CEO
GALWAY, Ireland--(BUSINESS WIRE)--Mar 12, 2025-- Signum Surgical, ('Signum' or 'the Company') the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. This press release features multimedia. View the full release here: Carol A. Burns, CEO, Signum Surgical (Photo: Business Wire) Ms. Burns' appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx ®, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide 1. Commercialization follows U.S. FDA Food and Drug Administration (FDA) De Novo clearance for BioHealx in 2024. The BioHealx device safely closes anal fistulas with a bioabsorbable implant that creates tissue apposition for primary healing, reducing lengthy and costly repeat procedures and diminishing the incidence of incontinence. With a distinguished career in the medical device industry, Carol has a proven track record of over 25 years founding, leading and successfully commercializing innovative therapies which include serration angioplasty, endovascular abdominal aortic aneurysm, and endoscopic vein harvesting. She previously co-founded and served as CEO of both Cagent Vascular and Intact Vascular. Additionally, she has held leadership positions at Embrella Cardiovascular (acquired by Edwards Lifesciences), Animas (acquired by Johnson & Johnson), Ventrica (acquired by Medtronic), and Guidant Corporation. Carol Burns, CEO, Signum Surgical, commented: 'I am delighted to join the Signum Surgical team to lead its next phase of growth. This innovative technology is the first treatment of fistula-in-ano which directly closes the fistula tract by tissue apposition, without sacrificing sphincter muscle function. We believe this technology will become the standard of care for the management of fistula-in-ano while also preserving fecal continence. The First-in-Human (FIH) study results, to be published later this year, showed excellent primary healing with no recurrence at 12+ months. Our commercial plan includes a Post Market Surveillance Study to build upon the FIH experience. We are excited to bring this novel treatment to market for the benefit of patients, surgeons, and the healthcare system.' Eoin Bambury, Co-Founder and Chief Technology Officer, added: 'With a proven track record of introducing innovative technologies, commercializing products in highly specialized fields and driving strategic growth, Carol is an ideal fit to lead the commercialization of BioHealx and our next phase of development.' Moshe Zilversmit, Co-Founder and Chief Innovation Officer, commented: 'Carol's deep expertise in the medical device industry and unwavering dedication to improving patient outcomes, aligns perfectly with our mission to revolutionize the surgical management of fistula-in-ano. We are delighted to have her on board.' About Anal Fistulas Anal fistula disease occurs more often in men, ages 18-50. Fistulas have complicated pathogenesis resulting in poor quality of life due to frequent recurrence, fecal incontinence, abscess, odor, and pain. Fistulas were first described by Hippocrates over 2,500 years ago, yet surgical procedures are often associated with suboptimal treatment results including incontinence and the need for repeat procedures due to recurrence. About BioHealx Technology The Signum Surgical BioHealx ® Anal Fistula Device is designed to close the fistula tract by tissue apposition to deliver primary healing. The device contains a single synthetic absorbable implant in the shape of a helical coil, preloaded into a special purpose single use delivery system. The device is designed for introduction and implant delivery under direct visualization. The BioHealx device has received FDA De Novo 510(k) Clearance. Signum Surgical, USA, Inc 175 Strafford Avenue, Suite 1 Wayne, PA 19087 Email: [email protected] Signum Surgical, LTD New Docks, The Docks Galway, Ireland, H91E2HV Media Contacts: FTI Consulting Patrick Berkery / Rugile Nenortaite Tel: +353 86 602 5988 / +353 86 277 9905 Email: [email protected] SOURCE: Signum Surgical Copyright Business Wire 2025. PUB: 03/12/2025 06:00 AM/DISC: 03/12/2025 06:00 AM
